Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.02M | 36.80M | 35.63M | 34.01M | 31.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 191.41M | 180.97M | 174.54M | 170.04M | 158.83M |
| Operating Income | -191.41M | -180.97M | -174.54M | -170.04M | -158.83M |
| Income Before Tax | -167.80M | -157.24M | -150.70M | -146.09M | -133.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -167.80 | -157.24 | -150.70 | -146.09 | -133.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.80M | -157.24M | -150.70M | -146.09M | -133.81M |
| EBIT | -191.41M | -180.97M | -174.54M | -170.04M | -158.83M |
| EBITDA | -189.32M | -178.83M | -172.39M | -167.93M | -156.76M |
| EPS Basic | -1.63 | -1.58 | -1.56 | -1.55 | -1.45 |
| Normalized Basic EPS | -1.02 | -0.99 | -0.97 | -0.97 | -0.90 |
| EPS Diluted | -1.63 | -1.58 | -1.56 | -1.55 | -1.45 |
| Normalized Diluted EPS | -1.02 | -0.99 | -0.97 | -0.97 | -0.90 |
| Average Basic Shares Outstanding | 411.58M | 400.29M | 388.61M | 377.18M | 369.62M |
| Average Diluted Shares Outstanding | 411.58M | 400.29M | 388.61M | 377.18M | 369.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |